Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
DaVita runs kidney dialysis centers and provides related medical care for people whose kidneys no longer work well enough on their own.
DaVita is one of America's two big dialysis companies, and its core business is simple to describe: it runs clinics where people with failing kidneys come in several times a week to have their blood cleaned by a machine. That process, dialysis, is what keeps them alive when their own kidneys can't filter waste anymore. DaVita treats patients in thousands of outpatient centers, mostly in the United States, and also offers home dialysis and some kidney-related lab and pharmacy services.
The money comes mostly from Medicare and private insurers. Dialysis is massively expensive, and the government pays for most of it because kidney failure qualifies people for Medicare regardless of age. DaVita bills for each treatment, and the treatments happen on a fixed schedule, week after week, often for years. That recurring, non-discretionary demand is why investors treat dialysis as a defensive business: people don't skip it when the economy sours. DaVita's main rival is Fresenius Medical Care, a German company that is the other giant in the field. The business has a reputation problem built into its economics. A government report and a major media investigation over a decade ago argued that DaVita and its competitors steered patients toward more profitable in-clinic treatment and had financial incentives that could cloud medical judgment. DaVita settled some related disputes and has pushed hard into home dialysis care, which is cheaper and often better for patients. It also faces constant pressure from insurers and from government efforts to control kidney care costs, and it has fought legal battles over how it bills for services.
Founder Kent Thiry built DaVita's peculiar culture, full of village metaphors and a famous "citizenship" ethos, before stepping back from the CEO role in 2015 after a long run. The company spent years buying back large amounts of its own stock, funded partly by debt, a bet that its steady cash flow would make the shrinking share count pay off. It has also sold off non-kidney businesses it once owned, including its medical group arm, to focus on the dialysis core. The upshot is a company that makes a lot of money doing something unpleasant and essential, while staying exposed to the two forces that can hurt it most: government payment rules and its own reputation.
Saved answer 路 last researched 6 Nov 2026